Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)

NCT02513771 is registered in ClinicalTrials.gov with Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections as lead sponsor.

NCT NCT02513771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02513771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
January 10, 2017
Enrollment
90 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection